Drug intelligence / Profile preview

CLYNAV

Development stage: Unknown
Lead developer: Elanco
Modality: Prophylactic Vaccines → Vaccines & Immunotherapeutics, DNA Vaccines → Plasmid DNA → DNA Therapeutics → Nucleic Acid Therapeutics
Administration: Intramuscular

Overview

CLYNAV is a DNA-based vaccine indicated for the active immunization of Atlantic salmon to reduce mortality and lesions associated with pancreas disease caused by Salmonid Alphavirus subtype 3 (SAV3). It was the first DNA vaccine for a food-producing species to be authorized in the European Union. The vaccine consists of a plasmid (pNNGH-SAV3-ns) that encodes the non-structural proteins of the virus; once injected, the host cells express these proteins to elicit a protective immune response. Originally developed by Elanco Animal Health, the product was acquired by Merck Animal Health in July 2024 as part of a broader acquisition of Elanco's aquaculture business.

Brand names: CLYNAV
Other names: Clynav

Beyond the preview

Go deeper on CLYNAV.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CLYNAV.

Explore the full profile